Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Jim Cash who wrote (279)	2/20/1999 9:45:00 AM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

The Point Is...... Jim, While performing my initial due-diligence on Immucor I happened across Serologicals as a potential purchaser of Immucor's products. SERO appears to be a major player in the blood industry. They perform clinical testing and sell critical antibodies used in blood products. Further investigation revealed that SERO has become very visible on Wall Street over time. This fact is evidenced through the coverage maintained by major firms such as Salomon Smith Barney and Lehman Brothers. A quick peak at SERO's web site reveals that it is well thought out, designed and packed with information. Finally, SERO has been growing sales while also executing an acquisition strategy of companies that compliment its core business. It is my hope that Corporate Communications can duplicate its SERO success with Immucor. SERO Business Summary SERO is a provider of specialty human antibody based products and services to healthcare companies. Services include donor recruitment and management and clinical testing services. For the nine months ended 9/27/98, revenues rose 26% to $91.5 million. Net income increased 38% to $12 million. Revenues reflect increased sales of anti-D antibodies and acquisitions. Net income also reflects decreased S/G/A expenses as a percentage of revenues due to effective leveraging. serologicals.com SERO & BLUD Quote Comparison quote.yahoo.com Regards, Tom